UBS Group Cuts Evolent Health (NYSE:EVH) Price Target to $14.00

Evolent Health (NYSE:EVH) had its price target decreased by UBS Group from $27.00 to $14.00 in a research report report published on Thursday,Benzinga reports. UBS Group currently has a buy rating on the technology company’s stock.

Other equities research analysts have also issued research reports about the stock. Truist Financial dropped their price target on shares of Evolent Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $38.00 to $16.00 in a research report on Friday, November 8th. Barclays reduced their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. JPMorgan Chase & Co. lowered their price target on Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, November 22nd. Finally, KeyCorp began coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $21.92.

Evolent Health Stock Up 2.1 %

EVH stock opened at $10.18 on Thursday. The stock has a market cap of $1.19 billion, a PE ratio of -11.18 and a beta of 1.45. The firm’s 50-day simple moving average is $11.86 and its 200 day simple moving average is $20.77. Evolent Health has a fifty-two week low of $9.88 and a fifty-two week high of $35.00. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Hedge Funds Weigh In On Evolent Health

Several large investors have recently made changes to their positions in the business. Quarry LP bought a new stake in shares of Evolent Health in the 2nd quarter worth approximately $32,000. Covestor Ltd grew its position in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Evolent Health during the 2nd quarter valued at $61,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Evolent Health during the 2nd quarter worth $148,000.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.